NCT00359294View on ClinicalTrials.gov

A Phase I Study of Zalypsis (PM00104) in Subjects With Advanced Malignant Solid Tumors or Lymphoma

PHASE1TerminatedINTERVENTIONAL

Enrollment

12

Participants

Timeline

Start Date

May 31, 2006

Primary Completion Date

September 30, 2008

Study Completion Date

September 30, 2008

Conditions

Solid TumorsLymphoma

Interventions

DRUG

PM00104

Intravenously over 1 hour daily for 5 days, every 3 weeks.

Trial Locations (2)

02115

Massachusetts General Hospital, Boston

19111-2497

Fox Chase Cancer Center, Philadelphia

Sponsors

Lead Sponsor

All Listed Sponsors

lead

PharmaMar

INDUSTRY